Company news

EyePoint, Inc. news in 2025

EyePoint, Inc.'s news releases, calls and decks from 2025, newest first.

View company

EyePoint to Present at the 44th Annual J.P. Morgan Healthcare Conference

December 16, 2025

EyePoint Announces Positive Recommendation from Independent Data Safety Monitoring Committee for Pivotal Phase 3 Trials for DURAVYU™ in Wet Age-Related Macular Degeneration

November 18, 2025

EyePoint Reports Third Quarter 2025 Financial Results and Highlights Recent Corporate Developments

November 4, 2025

EyePoint Announces Participation at Upcoming Investor Conferences

November 2, 2025

EyePoint to Report Third Quarter 2025 Financial Results on November 5, 2025

October 28, 2025

EyePoint Announces Proposed Public Offering of Common Stock

October 13, 2025

EyePoint Announces Pricing of Public Offering

October 13, 2025

EyePoint Announces Pivotal Phase 3 Program Initiation for DURAVYU™ in Diabetic Macular Edema

October 13, 2025

EyePoint Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Developments

August 6, 2025

EyePoint to Present at the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

August 5, 2025

EyePoint to Report Second Quarter 2025 Financial Results on August 6, 2025

July 29, 2025

EyePoint Completes Enrollment of Pivotal Phase 3 Trials for DURAVYU™ in Wet Age-Related Macular Degeneration

July 28, 2025

EyePoint Completes Enrollment in Pivotal Phase 3 LUGANO Trial of DURAVYU™ for Treatment of Wet Age-Related Macular Degeneration

May 26, 2025

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

May 15, 2025

EyePoint Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Developments

May 6, 2025

EyePoint to Report First Quarter 2025 Financial Results on May 7, 2025

April 29, 2025

EyePoint to Present at 2025 RBC Capital Markets Ophthalmology Virtual Conference

March 26, 2025

EyePoint Reports Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Corporate Developments

March 4, 2025

EyePoint to Report Fourth Quarter and Full-Year 2024 Financial Results on March 5, 2025

February 25, 2025

EyePoint to Present Corporate Update at TD Cowen 45th Annual Health Care Conference

February 24, 2025

EyePoint Announces Positive Six-Month Results for the Phase 2 VERONA Clinical Trial of DURAVYU™ for Diabetic Macular Edema Meeting Primary and Secondary Endpoints

February 4, 2025

EyePoint to Present at Guggenheim SMID Cap Biotech Conference

January 29, 2025

EyePoint Provides Company Update and Anticipated Development Milestones for 2025

January 12, 2025

EyePoint Appoints Renowned Retina Specialist and Industry Pioneer Reginald J. Sanders, M.D., FASRS to Board of Directors

January 7, 2025

Calls in 2025

Decks in 2025